Update on reverse transcriptase inhibitors in HIV disease.
Carr
A
A
Centre for Immunology, St. Vincent's Hospital, Sydney, Australia.
Loewenthal
M
M
Cooper
D A
DA
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D016049:Didanosine / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D011379:Prognosis; D018894:Reverse Transcriptase Inhibitors; D012307:Risk Factors; D016047:Zalcitabine / Q000008:administration & dosage* / Q000009:adverse effects; D015215:Zidovudine / Q000008:administration & dosage* / Q000009:adverse effects
D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D016047:Zalcitabine; D016049:Didanosine